MDX 210

Drug Profile

MDX 210

Alternative Names: Anti-breast-cancer-Trigger; Anti-ovary-cancer-Trigger

Latest Information Update: 22 Feb 2010

Price : $50

At a glance

  • Originator IDM S.A.
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; IgG receptor antagonists; Immunostimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 08 Apr 2005 Suspended - Phase-I for Breast cancer in USA (IV)
  • 08 Apr 2005 Suspended - Phase-II for Colorectal cancer in Sweden (IV)
  • 08 Apr 2005 Suspended - Phase-II for Prostate cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top